Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 119.48B, Vertex Pharmaceuticals(VRTX) trades at $470.87. The stock has a price-to-earnings ratio of 33.68.
As of 2026-02-09, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $467.98 and $478.54. The current price stands at $470.87, placing the stock +0.6% above today's low and -1.6% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 1.57M, compared to an average daily volume of 1.37M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Vertex Pharmaceuticals (NasdaqGS:VRTX) has entered an exclusive alliance with WuXi Biologics to develop and commercialize a trispecific T-cell Engager for B-cel...
Key Points Vertex's core franchise probably won't lead to any surprises, but newer launches could. The company should see significant pipeline progress this y...
Key Points The yield curve has steepened following President Trump's nomination of Kevin Warch as the next Fed chair. This could translate to higher inflation...
Analyst ratings
74%
of 35 ratingsMore VRTX News
Vertex Pharmaceuticals (VRTX) just expanded its autoimmune pipeline through a license and research agreement with WuXi Biologics for a trispecific T cell engage...
In early February 2026, WuXi Biologics announced a license and research service agreement granting Vertex Pharmaceuticals exclusive global rights to develop and...
WuXi Biologics announced that it has signed a license and research service agreement with Vertex Pharmaceuticals (VRTX) for a trispecific T-cell Engager for the...